GENRES and LIFE-Fin studies: EWASs of antihypertensive drug BP responses, Summary statistics
Description
Summary statistics of the EWASs of antihypertensive blood pressure responses in the GENRES (four drugs) and in the LIFE-Fin (two drugs) studies. Related article: Nuotio M-L, Sanez Tähtisalo H, Lahtinen A, Donner K, Fyhrquist F, Perola M, Kontula KK, Hiltunen TP. Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design. Epigenetics, published online Feb 25, 2022. (https://doi.org/10.1080/15592294.2022.2038418). Epigenome-wide analysis was performed on the antihypertensive responses to four different monotherapies in the GENRES Study and to two different monotherapies in the LIFE-Fin Study. The GENRES Study is randomized, placebo-controlled, cross-over and single-centre by design. Each subject underwent all the monotherapy periods (except for few withdrawals). The EWAS study included ca. 200 Finnish males, aged 35 to 59 years. The LIFE-Fin Study is part of the LIFE Study, including the Finnish subjects with DNA samples. The EWAS study included ca. 200 subjects from both the atenolol and the losartan arms of the study. The analytical and statistical methods are described in the article. Contact address: timo.hiltunen@hus.fi